Abstracts tagged "Lupus nephritis"

Abstract Number: 1458 • ACR Convergence 2023
Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity
Kittikorn Wangriatisak¹, Francesca Faustini², Charlotte de Vries³, Ravi Kumar Sharma⁴, Caroline Grönwall⁵, Prapaporn Pisitkun⁶, Patchanee Chootong⁷, Vivianne Malmström⁵ and Iva Gunnarsson⁸, ¹Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Thailand ; Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bankok, Thailand, ⁷Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand, ⁸Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Sweden, Stockholm, Sweden
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), which is characterized by abnormal B-cell activation and their…
Abstract Number: 1579 • ACR Convergence 2023
Sodium-Glucose Co-transporter-2 Inhibitors and the Risk of Cardiac and Renal Outcomes in Systemic Lupus Erythematosus
April Jorge¹, Baijun Zhou¹, Natalie McCormick¹, Chio Yokose¹, Yuqing Zhang² and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ³Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2) have benefits on kidney and cardiovascular (CV) outcomes that are largely independent of glycemic control. These benefits have been demonstrated…
Abstract Number: 2297 • ACR Convergence 2023
Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis
Laura Patricia Whittall Garcia¹, Dafna Gladman², Murray Urowitz³, Zahi Touma⁴ and Joan Wither¹, ¹University Health Network, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
Background/Purpose: Type I Interferons (IFN-I) play a role in SLE and Lupus Nephritis (LN) pathogenesis. We have recently shown that IFN-I gene expression predicts the…
Abstract Number: 0577 • ACR Convergence 2023
Analysis of Intracytoplasmic Toll – Like Receptors (TLRs) and MyD88 Expression in B Cell Subsets in Patients with Lupus Nephritis
Michelle Patricia Loeza-Uribe¹, Michelle Nicolle Espinoza-Carranza¹, Yatzil Reyna-Juárez¹, Beatriz Alcalá-Carmona¹, Nancy Raquel Mejía-Domínguez², Guillermo Juárez-Vega², José Luis Maravillas-Montero², Karina Santana-de Anda¹, José Jiram Torres-Ruiz¹ and Diana Gómez-Martín¹, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Mexico
Background/Purpose: Intrinsic signaling of intracytoplasmic TLRs (7 and 9) and MyD88 in B cells (BC) plays an important role in the development and pathogenesis of…
Abstract Number: 0899 • ACR Convergence 2023
Complement Factor I (CFI) Gene Expression by Kidney Tubular Cells Is Increased in Lupus Nephritis Patients with Interstitial Fibrosis and Tubular Atrophy
Shudan Wang¹, John Greally², Masako Suzuki³, Jee-Young Moon², Tao Wang², Yvonne M Saenger², Brad Rovin⁴ and J. Michelle Kahlenberg⁵, ¹Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Texas A&M University, College Station, TX, ⁴Ohio State University, Columbus, OH, ⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Tubulointerstitial injury is a strong predictor of progression to kidney failure in lupus nephritis (LN). Prior animal studies suggest intrarenal complement activation has an…
Abstract Number: 1464 • ACR Convergence 2023
Lupus Flares More Common in Patients on Dialysis Compared to After Renal Transplant: A Systematic Review and Meta-analysis
Omer Pamuk¹, Ansaam Daoud², Loai Dweik³, Niraj Desai⁴ and sarfaraz Hasni⁵, ¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²University Hospitals, Case Western Reserve University, Akron, OH, ³Cleveland Clinic Akron General, Akron, OH, ⁴Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, OH, ⁵Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: End-stage renal disease (ESRD) may develop in up to 20% of patients with lupus nephritis (LN). The SLE disease activity generally declines after the…
Abstract Number: 1585 • ACR Convergence 2023
Defining Neutrophil-Mediated Renal Damage Triggered by Ultraviolet (UV) Skin Exposure
Angelique Cortez¹, Lindsay Mendyka², Fred Kolling³, Michael Whitfield¹ and Sladjana Skopelja-Gardner⁴, ¹Dartmouth College, Hanover, NH, ²Dartmouth Hitchcock, Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Dartmouth-Hitchcock, Lebanon, NH
Background/Purpose: Lupus (SLE) is one of the leading causes of death in young women in the United States. Roughly ~80% of SLE patients experience sensitivity…
Abstract Number: 2310 • ACR Convergence 2023
Machine Learning Approaches for Prediction of Renal Flares in Systemic Lupus Erythematosus: Knowledge-Driven Models Outperformed Data-Driven Models
Nursen Cetrez¹, Julius Lindblom¹, Raffaele Da Mutten², Dionysis Nikolopoulos² and Ioannis Parodis¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden
Background/Purpose: Renal flares in patients with SLE result in significant nephron loss. Thus, identification of reliable early signals of impending renal flares is anticipated to…
Abstract Number: 0578 • ACR Convergence 2023
Prospective Observational Study of Microvascular C5b-9 Deposition in Non-lesional Skin in Systemic Lupus Erythematosus Patients and Its Correlation with Active Lupus Nephritis
Meghan Anderson¹, Cynthia Magro² and H Michael Belmont³, ¹New York University, New York, NY, ²Weill Cornell Medicine, New York, NY, ³NYU School of Medicine, New York, NY
Background/Purpose: Tissue damage in LN is mediated by immune complex activation of the classic complement pathway (PMID 23929771). In a study of LN, renal C5b-9…
Abstract Number: 0908 • ACR Convergence 2023
Association of Biologic Sex with Glycosphingolipids and the N-glycome in Lupus Nephritis and Renal Mesangial Cell Function
Tammy Nowling, bethany wolf, Calvin Blaschke, Richard Drake, Sandra Sanchez, Mariia Stefanenko, Mykhailo Fedoriuk, Oleg Palygin, Hongxia Bai and Jessalyn Rodgers, Medical University of South Carolina, Charleston, SC
Background/Purpose: SLE primarily afflicts women and many SLE patients develop nephritis, a serious complication of lupus. Identification of biomarkers and the pathogenic mechanisms underlying LN…
Abstract Number: 1471 • ACR Convergence 2023
A Comparative Study of Lupus Nephritis Class II and IgA Nephropathy: Renal Disease Other Than Lupus Nephritis in Systemic Lupus Erythematosus Patients
Eun song Kang¹ and Seokchan Hong², ¹Korea University Ansan Hospital, Seoul, South Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Background/Purpose: Lupus nephritis (LN) is one of major organ involvement of SLE and renal biopsy is commonly performed in SLE patients suspected of having LN…
Abstract Number: 1598 • ACR Convergence 2023
Single-cell Spatial Proteomics Identifies Intraglomerular Myeloid Cells in Membranous Lupus Nephritis
Chen-Yu Lee¹, Caleb Marlin², Xiaoping Yang¹, Tayte Stephens², Alessandra Ida Celia³, Jeff Hodgin⁴, Peter Izmirly⁵, H Michael Belmont⁶, Jill Buyon⁷, Chaim Putterman⁸, Judith James², the Accelerating Medicines Partnership in RA/SLE⁹, Michelle Petri¹⁰, Joel Guthridge², Avi Rosenberg¹¹ and Andrea Fava¹, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³John Hopkins University of Medicine, Rome, Italy, ⁴University of Michigan, Ann Arbor, MI, ⁵New York University School of Medicine, New York, NY, ⁶NYU School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸Albert Einstein College of Medicine, Bronx, NY, ⁹Multiple, Multiple, ¹⁰Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ¹¹Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Lupus nephritis (LN) leads to end-stage kidney disease (ESKD) in more than 20% of patients despite optimal treatment. Up to 30% of LN patients…
Abstract Number: 2314 • ACR Convergence 2023
Comparison of Disease Severity and Outcomes in Adolescent-Onset and Young Adult-Onset Systemic Lupus Erythematosus
Emma Materne¹, Baijun Zhou¹, Hyon K. Choi², Yuqing Zhang³ and April Jorge¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Adolescent-onset SLE is associated with more severe disease than adult-onset SLE, but young adults may also experience adverse outcomes. We sought to compare disease…
Abstract Number: 0593 • ACR Convergence 2023
Lupus Nephritis of the Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
María laiño¹, Monica Enguita², Pablo Navarro³, Javier Loricera⁴, Angel Garcia-Aparicio⁵, Carmen Lasa⁶, Vanesa Calvo Río⁷, Adela Gallego⁸, Clara Moriano Morales⁹, Javier Narvaez¹⁰, MARIA IRENE CARRION BARBERA¹¹, Jordi Camins-Fàbregas¹², Joaquin Maria Belzunegui Otano¹³, Ana Urruticoechea¹⁴, Leticia del Olmo Perez¹⁵, Santos Castañeda¹⁶, Patricia Quiroga¹⁶, Ivette Casafont-Sole¹⁷, Juan Ramon De Dios Jimenez De Aber¹⁸, Marta López¹⁹, Judit Font Urgelles²⁰, Rafaela Ortega Castro²¹, Marta Garijo Bufort²², Jorge Juan Fragio²³, Ignacio Vázquez²⁴, Mamen Ortega²⁵, Aaron Fariñas²⁶, Cilia Peralta²⁷, Juan María Blanco²⁸, Sergi Heredia Martin²⁹, Maria Valvanera Pinillos³⁰, Eztizen Labrador-Sánchez³¹, Piter Jose Cossio Jimenez³², Carlos Vazquez Galeano³³ and Vicente Aldasoro¹, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Navarrabiomed-Unidad de Metodología, Pamplona, Spain, ³Rheumatology, Hospial Universitario Puerta de Hierro, Majadahonda, Spain, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Hospital Universitario de Toledo, Toledo, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ⁷Valdecilla Hospital, Santander, Spain, ⁸Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ⁹Rheumatology, Hospital Universitario de León, León, Spain, ¹⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ¹¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹²Hospital General de Granollers, Granollers, Spain, ¹³University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁴Hospital Can Misses, Ibiza, Spain, ¹⁵Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain, ¹⁶Hospital Universitario de la Princesa, Madrid, Spain, ¹⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁸Hospital de Araba, Alava, Spain, ¹⁹Hospital Universitario Arava, Pamplona, Spain, ²⁰Hospital Universitario German Trias i Pujol,, Badalona, Spain, ²¹Hospital Reina Sofía, Cordoba, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Hospital General Universitario Valencia, Valencia, Spain, ²⁴H. U. Dr. Peset, Valencia, Spain, ²⁵Hospital Universitario de Getafe, Getafe, Spain, ²⁶Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²⁷Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ²⁸Hospital Universitario de Basurto, Bilbao, Spain, ²⁹Complex Hospitalari Moisès Broggi, Barcelona, Spain, ³⁰Hospital Universitario San Pedro, Logroño, Spain, ³¹Hospital Universitario San Pedro, Laguardia, Spain, ³²HOSPITAL REINA SOFIA, Tudela, Spain, ³³ZARAGOZA, Madrid, Spain
Background/Purpose: Belimumab (BLM) is a B-cell stimulating factor (BlyS) monoclonal antibody, approved in 2022 for the treatment of lupus nephritis (NL) and since 2011 for…
Abstract Number: 0911 • ACR Convergence 2023
Spatial Transcriptomics Reveals Normal-density and Low-density Neutrophils Are More Prevalent Than Macrophages in Lupus Nephritis Glomeruli, and Urine DNA Methylation Analyses Capture Both Myeloid Populations
Sladjana Skopelja-Gardner¹, Joshua Skydel², Alecia Roy³, Brenna Kerin³, James Whitley³, Fred Kolling⁴, Noelle Kosarek⁴, Michelle Petri⁵, Andrea Fava⁶, Lucas Salas⁷ and Christopher Burns³, ¹Department of Medicine, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, ²Dartmouth-Hitchcock Medical Center, Lebanon, NH, ³Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth, Hanover, NH, ⁵Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁶Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Despite compelling evidence that normal-density (NDN) and low-density neutrophils (LDN) are activated in the blood of lupus patients, their role in lupus nephritis (LN)…

« Previous Page
1
…
7
8
9
10
11
…
37
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.